Mesoblast/$MESO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Mesoblast
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Ticker
- $MESO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 108
- Headquarters
- Melbourne, Australia
- Website
- www.mesoblast.com
Mesoblast Metrics
BasicAdvanced
$1.9B
-
-$0.04
0.81
-
Price and volume
Market cap
$1.9B
Beta
0.81
52-week high
$21.50
52-week low
$11.89
Average daily volume
284K
Financial strength
Current ratio
2.435
Quick ratio
1.98
Long term debt to equity
0.2
Total debt to equity
0.224
Interest coverage (TTM)
-2.58%
Profitability
EBITDA (TTM)
-44.605
Gross margin (TTM)
80.02%
Net profit margin (TTM)
-47.82%
Operating margin (TTM)
-42.62%
Effective tax rate (TTM)
-1.08%
Revenue per employee (TTM)
$1,110,000
Management effectiveness
Return on assets (TTM)
-4.11%
Return on equity (TTM)
-9.86%
Valuation
Price to revenue (TTM)
151.832
Price to book
4.95
Price to tangible book (TTM)
1,383.05
Price to free cash flow (TTM)
-408.199
Free cash flow yield (TTM)
-0.24%
Free cash flow per share (TTM)
-0.035
Growth
Revenue change (TTM)
599.21%
Earnings per share change (TTM)
-47.51%
3-year revenue growth (CAGR)
152.15%
10-year revenue growth (CAGR)
10.95%
3-year earnings per share growth (CAGR)
-25.01%
10-year earnings per share growth (CAGR)
14.53%
What the Analysts think about Mesoblast
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Analyst projections of the future price of Mesoblast stock.
Bulls say / Bears say
Ryoncil’s US launch is gaining traction: net revenue reached US$115 million in FY2026, and first-quarter FY2027 revenue rose 44% year on year to US$28 million. The latest quarter also recorded the highest monthly number of new patient starts in September. (GlobeNewswire, OTC Markets)
The latest cash report suggests the commercial business is helping fund operations: cash was US$99 million at quarter-end, while operating cash spend fell to US$2.1 million from US$14.9 million a year earlier. That gives Mesoblast more scope to advance its programmes without an immediate need to raise equity. (GlobeNewswire)
Mesoblast has several potential growth catalysts beyond its current paediatric product: it completed treatment in its 350-patient Phase 3 chronic low-back-pain trial, and the FDA has confirmed it may proceed with a BLA filing for a heart-failure complication in patients with an LVAD. These programmes could broaden the business if the clinical and regulatory steps succeed. (GlobeNewswire)
Despite its first full commercial year, Mesoblast remained loss-making in FY2026, with a US$57.5 million net loss and US$43.8 million of operating cash use. Its US$125 million credit facility carries 8% interest, so growing sales have not yet removed the need to manage substantial costs and debt. (StockTitan)
Ryoncil is still the main commercial product, and its approved use is limited to children with steroid-refractory acute graft-versus-host disease. Expansion into adults could open a larger market, but the registration trial is only enrolling, leaving that growth dependent on future clinical and regulatory success. (GlobeNewswire)
The chronic low-back-pain opportunity remains unproven: although treatment in the Phase 3 trial is complete, its key 12-month pain-reduction results are still due next year. A disappointing result would undermine an important part of Mesoblast’s pipeline-led growth case. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Mesoblast Financial Performance
Revenues and expenses
Mesoblast Earnings Performance
Company profitability
Upcoming events
No upcoming events
Mesoblast News
AllArticlesVideos
Funds containing Mesoblast
Fund name | Fund size | $MESO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.05% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.